drugset / Trial / NCT06057935

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

NCT06057935 ↗

Phase 2 Recruiting 64 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Timeline

Start
2023-09-21
Primary completion
2028-09-21
Completion
2028-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Cisplatin Other / unclassified — Intravenous
Subject Pemetrexed Small molecule — Intravenous